United Kingdom

ViiV Healthcare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

ViiV Healthcare Gets FDA Approval of an Expanded Indication for Dovato (dolutegravir/lamivudine)

Lead Product(s): Dolutegravir,Lamivudine

Therapeutic Area: Infections and Infectious Diseases Product Name: Dovato

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 06, 2020

Details:

Dovato allows adults living with HIV to reduce the number of antiretroviral therapies they take each day, while maintaining efficacy and high barrier to resistance comparable to tenofovir-based regimens of at least three drugs.

ViiV Healthcare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Viiv Healthcare Presents Positive Data from First-Ever Implementation Research Study on How Best to Integrate an Investigational Once-Monthl...

Lead Product(s): Cabotegravir,Rilpivirine

Therapeutic Area: Infections and Infectious Diseases Product Name: Cabenuva

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 04, 2020

Details:

ViiV Healthcare announced positive initial findings from the CUSTOMIZE trial, which aims to identify successful methods of implementing the investigational once-monthly, long-acting regimen of cabotegravir and rilpivirine for the treatment of HIV-1 into clinical practice.

ViiV Healthcare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

ViiV Healthcare Announces US FDA Approval for Rukobia (fostemsavir)

Lead Product(s): Fostemsavir,Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Rukobia

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 02, 2020

Details:

In a phase III study, a majority (60%) of heavily treatment-experienced adults randomized to receive Rukobia with an optimized background therapy achieved and maintained viral suppression through 96 weeks, addressing a critical unmet need.

ViiV Healthcare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

ViiV Healthcare to Present New Data on Long-Acting Regimens for HIV Prevention and Treatment, Alongside Extensive Insights into the Evolving...

Lead Product(s): Cabotegravir,Rilpivirine

Therapeutic Area: Infections and Infectious Diseases Product Name: Cabenuva

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 02, 2020

Details:

Comapany to present the final efficacy analysis from the global HPTN 083 study evaluating cabotegravir for HIV prevention.

ViiV Healthcare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

FDA approves ViiV Healthcare’s Tivicay to treat HIV in children

Lead Product(s): Dolutegravir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2020

Details:

U.S FDA has approved Tivicay PD (dolutegravir) tablets for oral suspension, which are used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in paediatric patients.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

ViiV Healthcare

ViiV Healthcare Gets FDA Approval of an Expanded Indication for Dovato (dolutegravir/lamivudine)

ViiV Healthcare

Viiv Healthcare Presents Positive Data from First-Ever Implementation Research Study on How Best to Integrate an Investigational Once-Monthl...

ViiV Healthcare

ViiV Healthcare Announces US FDA Approval for Rukobia (fostemsavir)

ViiV Healthcare

ViiV Healthcare to Present New Data on Long-Acting Regimens for HIV Prevention and Treatment, Alongside Extensive Insights into the Evolving...

ViiV Healthcare

FDA approves ViiV Healthcare’s Tivicay to treat HIV in children